NASDAQ:STRO

Sutro Biopharma Stock Forecast, Price & News

$19.68
-0.30 (-1.50 %)
(As of 09/17/2021 04:00 PM ET)
Add
Compare
Today's Range
$19.56
$20.36
50-Day Range
$16.88
$22.38
52-Week Range
$9.73
$28.30
Volume1.06 million shs
Average Volume231,833 shs
Market Capitalization$908.23 million
P/E RatioN/A
Dividend YieldN/A
Beta0.76
30 days | 90 days | 365 days | Advanced Chart
Receive STRO News and Ratings via Email

Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter.


Sutro Biopharma logo

About Sutro Biopharma

Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.89 out of 5 stars

Medical Sector

671st out of 1,350 stocks

Biological Products, Except Diagnostic Industry

107th out of 193 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Sutro Biopharma (NASDAQ:STRO) Frequently Asked Questions

Is Sutro Biopharma a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Sutro Biopharma stock.
View analyst ratings for Sutro Biopharma
or view top-rated stocks.

What stocks does MarketBeat like better than Sutro Biopharma?

Wall Street analysts have given Sutro Biopharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Sutro Biopharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Sutro Biopharma's next earnings date?

Sutro Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Sutro Biopharma
.

How were Sutro Biopharma's earnings last quarter?

Sutro Biopharma, Inc. (NASDAQ:STRO) announced its quarterly earnings data on Sunday, August, 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.41) by $0.28. The business earned $28.05 million during the quarter, compared to analyst estimates of $13.80 million. Sutro Biopharma had a negative trailing twelve-month return on equity of 32.92% and a negative net margin of 114.69%.
View Sutro Biopharma's earnings history
.

How has Sutro Biopharma's stock been impacted by Coronavirus (COVID-19)?

Sutro Biopharma's stock was trading at $8.11 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, STRO stock has increased by 142.7% and is now trading at $19.68.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for STRO?

4 brokerages have issued 1-year target prices for Sutro Biopharma's stock. Their forecasts range from $22.00 to $37.00. On average, they anticipate Sutro Biopharma's stock price to reach $29.40 in the next year. This suggests a possible upside of 49.4% from the stock's current price.
View analysts' price targets for Sutro Biopharma
or view top-rated stocks among Wall Street analysts.

Who are Sutro Biopharma's key executives?

Sutro Biopharma's management team includes the following people:
  • William J. Newell, President, Chief Executive Officer & Director
  • Nicki Vasquez, Senior VP-Operations & Alliance Management
  • Edward C. Albini, Chief Financial Officer & Secretary
  • Trevor Hallam, Chief Scientific Officer & President-Research
  • Arturo Molina, Chief Medical Officer

What is William J. Newell's approval rating as Sutro Biopharma's CEO?

11 employees have rated Sutro Biopharma CEO William J. Newell on Glassdoor.com. William J. Newell has an approval rating of 100% among Sutro Biopharma's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Sutro Biopharma's key competitors?

What other stocks do shareholders of Sutro Biopharma own?

When did Sutro Biopharma IPO?

(STRO) raised $75 million in an IPO on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Sutro Biopharma's stock symbol?

Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO."

Who are Sutro Biopharma's major shareholders?

Sutro Biopharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.87%), Franklin Resources Inc. (6.17%), State Street Corp (4.84%), First Light Asset Management LLC (4.49%), Vanguard Group Inc. (4.47%) and Baillie Gifford & Co. (3.89%). Company insiders that own Sutro Biopharma stock include Arturo Md Molina, John Gordon Freund, Trevor Hallam and William J Newell.
View institutional ownership trends for Sutro Biopharma
.

Which institutional investors are selling Sutro Biopharma stock?

STRO stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Federated Hermes Inc., State Street Corp, Marshall Wace LLP, Marshall Wace LLP, Ikarian Capital LLC, and Tekla Capital Management LLC.
View insider buying and selling activity for Sutro Biopharma
or view top insider-selling stocks.

Which institutional investors are buying Sutro Biopharma stock?

STRO stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Northern Trust Corp, Franklin Resources Inc., Point72 Asset Management L.P., Opaleye Management Inc., Geode Capital Management LLC, Baillie Gifford & Co., and Panagora Asset Management Inc.. Company insiders that have bought Sutro Biopharma stock in the last two years include Arturo Md Molina, and William J Newell.
View insider buying and selling activity for Sutro Biopharma
or or view top insider-buying stocks.

How do I buy shares of Sutro Biopharma?

Shares of STRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sutro Biopharma's stock price today?

One share of STRO stock can currently be purchased for approximately $19.68.

How much money does Sutro Biopharma make?

Sutro Biopharma has a market capitalization of $908.23 million and generates $42.72 million in revenue each year. The company earns $-32,130,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis.

How many employees does Sutro Biopharma have?

Sutro Biopharma employs 192 workers across the globe.

What is Sutro Biopharma's official website?

The official website for Sutro Biopharma is www.sutrobio.com.

Where are Sutro Biopharma's headquarters?

Sutro Biopharma is headquartered at 310 Utah Avenue Suite 150, South San Francisco CA, 94080.

How can I contact Sutro Biopharma?

Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The company can be reached via phone at (650) 392-8412 or via email at [email protected].


This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.